ATOS - Atossa Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
13.88M
Enterprise Value 3
-584.85k
Trailing P/E
N/A
Forward P/E 1
-1.01
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
0.97
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
0.04

Trading Information

Stock Price History

Beta (5Y Monthly) 3.37
52-Week Change 310.14%
S&P500 52-Week Change 325.98%
52 Week High 37.3900
52 Week Low 31.1900
50-Day Moving Average 31.5230
200-Day Moving Average 31.8049

Share Statistics

Avg Vol (3 month) 385.69k
Avg Vol (10 day) 380.26k
Shares Outstanding 59.13M
Float 9.1M
% Held by Insiders 10.57%
% Held by Institutions 12.82%
Shares Short (Dec 30, 2019) 4338.54k
Short Ratio (Dec 30, 2019) 43.73
Short % of Float (Dec 30, 2019) 43.73%
Short % of Shares Outstanding (Dec 30, 2019) 43.71%
Shares Short (prior month Nov 28, 2019) 4330.83k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:12
Last Split Date 3Apr 19, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-68.18%
Return on Equity (ttm)-130.53%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -16.7M
Net Income Avi to Common (ttm)-16.7M
Diluted EPS (ttm)-2.1870
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)15.29M
Total Cash Per Share (mrq)1.67
Total Debt (mrq)63.28k
Total Debt/Equity (mrq)0.42
Current Ratio (mrq)10.48
Book Value Per Share (mrq)1.57

Cash Flow Statement

Operating Cash Flow (ttm)-8.86M
Levered Free Cash Flow (ttm)-5M